KDOAM-25 citrate
Based on 9 publication(s) in Google Scholar
KDOAM-25 citrate is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor with IC50s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively. KDOAM-25 citrate increases global H3K4 methylation at transcriptional start sites and impairs proliferation in multiple myeloma MM1S cells.
For research use only. We do not sell to patients.
- Purity: 98.56%
- CAS No.: 2448475-08-7
- Formula: C21H33N5O9
- Molecular Weight:499.51
-
Storage:
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Epigenetics Compound Library
HY-L005
-
Histone Modification Research Compound Library
HY-L024
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Transcription Factor-Targeted Library
HY-L090
-
Targeted Diversity Library
HY-L099
-
Heterocyclic Compound Library
HY-L138
-
Highly Selective Inhibitors Library
HY-L158
-
Anti-Hematopathy Compound Library
HY-L171
-
Bioactive Compound Library Max
HY-L181
-
Epigenetics Compound Library Mini
HY-L005M
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Methylation Compound Library
HY-L203
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) KDOAM-25 citrate
More- Nat Cell Biol. 2024 Feb;26(2):263-277. [Abstract]
- Sci Adv. 2025 Jun 6;11(23):eadu2695. [Abstract]
- Clin Transl Med. 2024 Jun;14(6):e1692. [Abstract]
- Oncol Rep. 2026 Apr;55(4):79. [Abstract]
- Clin Exp Med. 2025 Nov 25;26(1):33. [Abstract]
- Cancer Res Commun. 2026 Mar 1;6(3):616-629. [Abstract]
- bioRxiv. 2024 October 03.
- Research Square Preprint. 2023 Dec 2.
- University of Gothenburg. 2023 Jun 27.
Biological Activity
|
KDM5 |
KDOAM-25 citrate inhibits most potently KDM5B with an IC50 of ～50 μM and the other KDM5 family members at concentrations above 100 μM. KDOAM-25 citrate shows no cellular activity on any of the other tested JmjC family members[1].
?
KDOAM-25 citrate is able to reduce the viability of MM1S cells with an IC50 of ～30 μM after a delay of 5-7 days[1].
?
KDOAM-25 citrate treatment results in a G1 cell-cycle arrest with an increased proportion of MM1S in G1 and a decrease of the proportion of cells in G2 without an increase in the proportion of cells in the apoptotic sub-G1 phase[1].
?
KDOAM-25 citrate (50 μM) increases with approximately twice as much H3K4me3 in in multiple myeloma cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2448475-08-7
-
Appearance Solid
-
Molecular Weight 499.51
-
Formula C21H33N5O9
-
Color Light yellow to yellow
-
SMILES
NC(C1=CC=NC(CNCC(N(CC)CCN(C)C)=O)=C1)=O.OC(CC(C(O)=O)(O)CC(O)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Nat Cell Biol
Single-cell multi-omics profiling of human preimplantation embryos identifies cytoskeletal defects during embryonic arrest. [Abstract]2024 Feb;26(2):263-277. PMID: 38238450 -
Sci Adv
Determining sex differences in aortic valve myofibroblast responses to drug combinations identified using a digital medicine platform. [Abstract]2025 Jun 6;11(23):eadu2695. PMID: 40479052 -
Clin Transl Med
Inhibition of HDAC2 sensitises antitumour therapy by promoting NLRP3/GSDMD-mediated pyroptosis in colorectal cancer. [Abstract]2024 Jun;14(6):e1692. PMID: 38804602 -
Oncol Rep
2026 Apr;55(4):79. PMID: 41789643 -
Clin Exp Med
Corin: a dual inhibitor for KDM1A/HDAC1, suppresses hepatocellular carcinoma by triggering cuproptosis. [Abstract]2025 Nov 25;26(1):33. PMID: 41286164 -
Cancer Res Commun
Mutant Isocitrate Dehydrogenase 1 Sensitizes Intrahepatic Cholangiocarcinoma Cells to MDM2 Inhibitors. [Abstract]2026 Mar 1;6(3):616-629. PMID: 41747217 -
-
-
Solvent & Solubility
DMSO : 200 mg/mL (400.39 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 100 mg/mL (200.20 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (10.01 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (10.01 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.0020 mL | 10.0098 mL | 20.0196 mL | 50.0490 mL |
| 5 mM | 0.4004 mL | 2.0020 mL | 4.0039 mL | 10.0098 mL | |
| 10 mM | 0.2002 mL | 1.0010 mL | 2.0020 mL | 5.0049 mL | |
| 15 mM | 0.1335 mL | 0.6673 mL | 1.3346 mL | 3.3366 mL | |
| 20 mM | 0.1001 mL | 0.5005 mL | 1.0010 mL | 2.5025 mL | |
| 25 mM | 0.0801 mL | 0.4004 mL | 0.8008 mL | 2.0020 mL | |
| 30 mM | 0.0667 mL | 0.3337 mL | 0.6673 mL | 1.6683 mL | |
| 40 mM | 0.0500 mL | 0.2502 mL | 0.5005 mL | 1.2512 mL | |
| 50 mM | 0.0400 mL | 0.2002 mL | 0.4004 mL | 1.0010 mL | |
| 60 mM | 0.0334 mL | 0.1668 mL | 0.3337 mL | 0.8342 mL | |
| 80 mM | 0.0250 mL | 0.1251 mL | 0.2502 mL | 0.6256 mL | |
| 100 mM | 0.0200 mL | 0.1001 mL | 0.2002 mL | 0.5005 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
KDOAM-25 citrate Related Classifications
HY-102047B Related Classifications
Powered by Bioz